AtheroPoint aims to revolutionize the screening, diagnosis, monitoring and management of cardiovascular disease (CVD).

Via the vascular window, AtheroPoint can diagnose early onset atherosclerosis, help to manage and monitor progression of the disease, calculate the risk of Transient Ischemic Attacks (TIA), and track the morphology of plaque buildup in order to determine optimal therapy, including pharmaceutical drug design and validation. A patented ultrasound image analysis (IA) software combined with a handheld imaging device allow AtheroPoint to transform the early discovery and treatment of CVD by providing reliable, cost-effective, automated, accurate, fast diagnostic and risk predictive data – ‘anytime/anywhere’.The Athero Mini Scan, using AtheroEdge software, offers a safe, non-invasive, reliable, fully-automated arterial image analysis with features not available in the current market.